Mechanical Thrombectomy Devices

Mechanical Thrombectomy Devices Market by Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and, Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurological and vascular diseases, increasing preference for minimally invasive procedures non-surgical procedures, and increasing product development activities among the key market players.

The mechanical thrombectomy devices market was valued at USD 849.70 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 1,434.78 million by 2032. The demand for mechanical thrombectomy devices is being propelled by several key factors that collectively underscore the market's strong growth. Foremost among these is the rising global prevalence of neurological and vascular disorders, including acute ischemic stroke and deep vein thrombosis, which continues to drive the need for effective and timely interventions. Additionally, there is a growing preference for minimally invasive and non-surgical treatment options among patients and healthcare providers. Another critical growth driver is the increasing pace of innovation and product development by key market players. Leading medical device manufacturers are consistently investing in advanced thrombectomy technologies, expanding their portfolios, and launching next-generation devices that improve procedural efficiency and clinical success rates. Together, these factors are shaping a favorable environment for sustained expansion in the mechanical thrombectomy devices market, positioning it for robust and consistent growth throughout the forecast period from 2025 to 2032.

Mechanical Thrombectomy Devices Market Dynamics:

According to the British Heart Foundation (2024), an estimated 56 million women and 45 million men worldwide were stroke survivors, reflecting the immense global burden of cerebrovascular disease. The same source also reported that, as of 2022, nearly 250 million people globally were living with coronary heart disease, further emphasizing the need for effective interventional solutions. These devices play a vital role in restoring blood flow by physically removing blood clots that obstruct arteries or veins, especially in acute, life-threatening conditions such as ischemic stroke or peripheral arterial thrombosis.

Additionally, the World Stroke Organization (2023), highlighted that one in four adults over the age of 25 would suffer a stroke in their lifetime, and over 110 million individuals worldwide had already experienced one. Complementing this, the Parkinson’s Foundation (2022), noted that approximately 90,000 new cases of Parkinson’s disease (PD) were diagnosed annually in the United States alone, with the number of affected individuals expected to reach 1.2 million by 2030. Parkinson’s especially in older individuals is at increased risk of stroke, including ischemic stroke, due to shared risk factors like hypertension, reduced mobility, and cardiovascular complications. Thus, these statistics underscore the rising incidence of neurological disorders, driving the demand for innovative and timely treatment options like mechanical thrombectomy.

Adding to this momentum, key market players are intensifying their R&D efforts to develop and commercialize next-generation thrombectomy systems. For instance, in March 2025, Inari Medical, part of Stryker, launched the Artix™ Thrombectomy System. Purpose-built to address the unique challenges of the peripheral arterial system, Artix combined aspiration and mechanical thrombectomy into a single, integrated platform. The system was designed to deliver enhanced procedural control and versatility, setting a new benchmark in arterial thrombectomy and significantly expanding treatment options for patients with peripheral arterial thromboembolic conditions. Such product innovations and strategic launches are expected to further propel market growth by improving clinical efficacy, reducing procedural risks, and expanding the treatable patient population.

However, the complications associated with mechanical thrombectomy devices and the high cost associated with mechanical thrombectomy procedures, among others are some of the key constraints that may limit the growth of the mechanical thrombectomy devices market.

Mechanical Thrombectomy Devices Market Segment Analysis:

Mechanical Thrombectomy Devices Market by Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and, Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the mechanical thrombectomy devices market, the clot retriever category is estimated to account for the largest market share in 2024. This can be attributed to the various advantages and applications provided by the clot retrievers used in the removal of blood clots. These devices are anticipated to witness significant growth in the coming years, driven by their critical role in restoring blood flow by mechanically removing thrombus or emboli from occluded blood vessels. By providing a minimally invasive alternative to traditional surgical interventions, clot retrievers facilitate faster patient recovery, reduce the risk of complications, and contribute to improved overall outcomes. 

A major factor driving this segment is the rising global prevalence of peripheral vascular and thrombotic disorders, such as peripheral artery disease (PAD), stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). According to the British Heart Foundation (2024), over 110 million individuals were affected by peripheral arterial (vascular) disease, while 94 million people globally were living with the effects of stroke. These figures highlight the urgent need for effective clot-removal technologies.

One of the key clinical benefits of clot retrievers is their ability to rapidly restore blood flow, a feature that is especially crucial in life-threatening conditions such as acute ischemic stroke. The minimally invasive design of these devices typically introduced through a small puncture site offers several patient-centric advantages, including shorter hospital stays, quicker return to function, and lower complication rates when compared to open surgery.

Recent clinical research has further strengthened the case for clot retrievers. Studies have demonstrated that mechanical thrombectomy using clot retrievers provides superior clinical outcomes compared to medical therapy alone, particularly for patients suffering from large vessel occlusions. Importantly, these studies have supported the extension of the treatment window for mechanical thrombectomy to up to 24 hours from symptom onset in carefully selected patients, broadening the scope of treatment and improving survival rates.

Technological innovation continues to play a pivotal role in this segment. A recent example is the April 2025 commercial launch of the Pounce™ XL Thrombectomy System by Surmodics. This next-generation clot retriever was designed for the rapid, non-surgical extraction of acute or chronic clots from the iliac and femoral arteries, eliminating the need for thrombolytic drugs. Such advancements address the critical need for safer, more efficient clot removal options, particularly for patients who are not suitable for thrombolytic therapy.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of mechanical thrombectomy devices across the globe.

North America is expected to dominate the overall mechanical thrombectomy devices market:

North America is expected to hold the largest share of the mechanical thrombectomy devices market in 2024, driven by several key factors. The region’s dominance can be attributed to the high prevalence of peripheral and coronary vascular diseases, the rapidly growing geriatric population, and the continuous innovation and product launches by leading medical device companies based in the region. These elements, combined with advanced healthcare infrastructure, favorable reimbursement policies, and increasing awareness of minimally invasive procedures, are expected to sustain North America's leading position in the global market.

According to data from the Centers for Disease Control and Prevention (2024), over 795,000 individuals in the United States experience a stroke each year. Notably, nearly 185,000 of these strokes, accounting for approximately 1 in 4 cases occur in individuals with a history of prior strokes. Additionally, the CDC reports that approximately 900,000 people in the U.S. are affected by venous thromboembolism (VTE) annually, further underlining the substantial burden of thromboembolic diseases. These increasing figures highlight the growing need for mechanical thrombectomy devices, which are designed to physically remove blood clots and restore normal circulation in affected vessels thereby escalating the overall market across the region.

Additionally, according to data provided by the Centers for Disease Control and Prevention (2023), an estimated 6.7 million people aged 65 years or older were living with Alzheimer’s disease, with projections indicating this number could nearly triple, reaching 14 million by 2060 in the United States. Alzheimer’s patients, especially in advanced stages, often experience vascular complications such as cerebral amyloid angiopathy, hypertension, and impaired blood flow, all of which elevate stroke risk. This growing overlap between Alzheimer’s and stroke cases increases the demand for prompt, effective stroke treatments including mechanical thrombectomy across the region.

In addition to rising disease prevalence, the North America market is also benefiting from technological innovation and new product launches. For instance, in September 2024, Vesalio announced the U.S. commercialization of the pVasc™ Thrombectomy System, a device designed for the non-surgical removal of peripheral occlusions. The pVasc™ system targets a wide range of emboli, from soft, acute clots to fibrin-rich, calcified ones, providing a fast, safe, and versatile treatment option. Such developments not only enhance treatment efficacy but also expand the range of conditions that can be managed with mechanical thrombectomy.

Mechanical Thrombectomy Devices Market Key Players: 

Some of the key market players operating in the mechanical thrombectomy devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.

Recent Developmental Activities in the Mechanical Thrombectomy Devices Market:

• In February 2025, Johnson & Johnson MedTech launched the CEREGLIDE™ 92 Catheter System for the treatment of acute ischemic stroke. This innovative system enables physicians to restore blood flow in the brain by using CEREGLIDE 92 to insert aspiration catheters during thrombectomy procedures. 
• In September 2024, Argon Medical Devices announced the launch of the CLEANER Vac™ Thrombectomy System, specifically designed for the removal of blood clots from the peripheral venous vasculature. This disposable, large-bore aspiration system was engineered to quickly and effectively remove thrombus (blood clots) from vessels with restricted blood flow.
• In January 2023, Penumbra, Inc. announced FDA clearance and the launch of the Lightning Flash™, specifically designed to address venous and pulmonary thrombus. Lightning Flash™ offers enhanced performance in thrombectomy procedures, enabling physicians to efficiently remove clots from challenging vascular locations.  

Key Takeaways from the Mechanical Thrombectomy Devices Market Report Study

• Market size analysis for current mechanical thrombectomy devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the mechanical thrombectomy devices market.
• Various opportunities available for the other competitors in the mechanical thrombectomy devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current mechanical thrombectomy devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for mechanical thrombectomy devices market growth in the coming future?

Target Audience Who Can Benefit from this Mechanical Thrombectomy Devices Market Report Study

• Mechanical thrombectomy device product providers
• Research organizations and consulting companies 
• Mechanical thrombectomy devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in mechanical thrombectomy devices
• Various end-users who want to know more about the mechanical thrombectomy devices market and the latest technological developments in the mechanical thrombectomy devices market.  

Frequently Asked Questions for the Mechanical Thrombectomy Devices Market:

1. What are mechanical thrombectomy devices?

• Mechanical thrombectomy devices are medical tools used to physically remove blood clots (thrombi) from blood vessels, typically in cases of stroke, deep vein thrombosis, or pulmonary embolism. These devices restore blood flow by using mechanical methods, such as aspiration or clot retrieval, and are often employed in minimally invasive procedures to improve patient outcomes.

2. What is the market for mechanical thrombectomy devices?

•  The mechanical thrombectomy devices market was valued at USD 849.70 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 1,434.78 million by 2032

  .

3. What are the drivers for the mechanical thrombectomy devices market?

• The demand for mechanical thrombectomy devices is driven by key factors that highlight the market's growth potential from 2025 to 2032. The rising global prevalence of neurological and vascular disorders, such as acute ischemic stroke and deep vein thrombosis, continues to fuel the need for effective interventions. Additionally, there is increasing patient and healthcare provider preference for minimally invasive treatments. Another significant driver is the rapid pace of innovation, with leading manufacturers investing in next-generation thrombectomy technologies that enhance procedural efficiency and clinical outcomes. Together, these factors are set to sustain strong market growth throughout the forecast period from 2025 to 2032.

4. Who are the key players operating in the mechanical thrombectomy devices market?

• Some of the key market players operating in the mechanical thrombectomy devices market include Stryker, Abbott Laboratories, Boston Scientific Corporation, Argon Medical Devices, Contego Medical, Inc., Mermaid Medical, Surmodics, Inc., Penumbra, Inc., Medtronic, Johnson & Johnson Services, Inc., Edwards Lifesciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroPort Scientific Corporation, Thrombolex, phenox GmbH, Acandis GmbH, Inova, Vesalio Inc., ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., and others.

5. Which region has the highest share in the mechanical thrombectomy devices market?

• North America is anticipated to hold the largest market share in the mechanical thrombectomy devices market in 2024. This dominance is primarily driven by the high prevalence of peripheral and coronary vascular conditions, a growing geriatric population, and continuous product development and launches by key players in the region.